Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
Identifieur interne : 001902 ( Main/Exploration ); précédent : 001901; suivant : 001903Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
Auteurs : Marie Desplats [France] ; Tristan Pascart [France] ; Germain Jelin [France] ; Laurène Norberciak [France] ; Peggy Philippe [France] ; Eric Houvenagel [France] ; Vincent Goeb [France] ; René-Marc Flipo [France]Source :
- Clinical rheumatology [ 1434-9949 ] ; 2017.
Descripteurs français
- KwdFr :
- Abatacept (administration et posologie), Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Antirhumatismaux (administration et posologie), Enquêtes et questionnaires, Femelle, Humains, Injections sous-cutanées, Mâle, Perfusions veineuses, Polyarthrite rhumatoïde (traitement médicamenteux), Préférence du patient (), Sujet âgé, Études transversales.
- MESH :
- administration et posologie : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- Adulte d'âge moyen, Enquêtes et questionnaires, Femelle, Humains, Injections sous-cutanées, Mâle, Perfusions veineuses, Préférence du patient, Sujet âgé, Études transversales.
English descriptors
- KwdEn :
- Abatacept (administration & dosage), Aged, Antibodies, Monoclonal, Humanized (administration & dosage), Antirheumatic Agents (administration & dosage), Arthritis, Rheumatoid (drug therapy), Cross-Sectional Studies, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Patient Preference (statistics & numerical data), Surveys and Questionnaires.
- MESH :
- chemical , administration & dosage : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- drug therapy : Arthritis, Rheumatoid.
- statistics & numerical data : Patient Preference.
- Aged, Cross-Sectional Studies, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Surveys and Questionnaires.
Abstract
Choosing the subcutaneous (SC) route of administration of abatacept and tocilizumab is more cost-effective than the intravenous (IV) route. The objective of this study was to examine patients' reasons for choosing to keep with their IV infusions or to switch to subcutaneous SC injections. This study was based upon a self-administered questionnaire given to consecutive rheumatoid arthritis patients treated with abatacept or tocilizumab. Patients were asked to express their opinions concerning reasons explaining why they chose to keep the IV route or switch to the SC route. A total of 201 questionnaires completed by 127 patients treated by tocilizumab and 74 by abatacept were analysed. Overall, 45.8% of the patients chose to keep the IV route of administration. Another ongoing SC treatment was noted more often in patients choosing the SC route (15.9 versus 4.3%, p < 0.05). Reasons guiding the choice of the SC route were concerns about repeated hospital day-care (72%), greater autonomy with SC injections (38.7%) and economic considerations (21.5%). Reasons associated with choosing to maintain the IV route were worries about a lack of follow-up (72.1%), the absence of medical assistance during the SC injection (61.2%), maintaining social relationships with other patients developed at the hospital (40.5%), lower frequency of injection (32.9%), fear of adverse events (27.7%) and fear of SC injections (17.9%). Patients reject the SC switch from the IV route of tocilizumab and abatacept mainly because of fears about the unknown SC route, while those who accept it find it more convenient.
DOI: 10.1007/s10067-017-3587-8
PubMed: 28255739
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C16
- to stream PubMed, to step Curation: 000C16
- to stream PubMed, to step Checkpoint: 000C29
- to stream Ncbi, to step Merge: 001494
- to stream Ncbi, to step Curation: 001494
- to stream Ncbi, to step Checkpoint: 001494
- to stream Main, to step Merge: 001901
- to stream Main, to step Curation: 001902
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.</title><author><name sortKey="Desplats, Marie" sort="Desplats, Marie" uniqKey="Desplats M" first="Marie" last="Desplats">Marie Desplats</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex, France. pascart.tristan@ghicl.net.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lomme</settlement></placeName></affiliation></author><author><name sortKey="Jelin, Germain" sort="Jelin, Germain" uniqKey="Jelin G" first="Germain" last="Jelin">Germain Jelin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Picardie</region><settlement type="city">Amiens</settlement></placeName></affiliation></author><author><name sortKey="Norberciak, Laurene" sort="Norberciak, Laurene" uniqKey="Norberciak L" first="Laurène" last="Norberciak">Laurène Norberciak</name><affiliation wicri:level="3"><nlm:affiliation>Department of biomedical research, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of biomedical research, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lomme</settlement></placeName></affiliation></author><author><name sortKey="Philippe, Peggy" sort="Philippe, Peggy" uniqKey="Philippe P" first="Peggy" last="Philippe">Peggy Philippe</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Houvenagel, Eric" sort="Houvenagel, Eric" uniqKey="Houvenagel E" first="Eric" last="Houvenagel">Eric Houvenagel</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lomme</settlement></placeName></affiliation></author><author><name sortKey="Goeb, Vincent" sort="Goeb, Vincent" uniqKey="Goeb V" first="Vincent" last="Goeb">Vincent Goeb</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Picardie</region><settlement type="city">Amiens</settlement></placeName></affiliation></author><author><name sortKey="Flipo, Rene Marc" sort="Flipo, Rene Marc" uniqKey="Flipo R" first="René-Marc" last="Flipo">René-Marc Flipo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28255739</idno><idno type="pmid">28255739</idno><idno type="doi">10.1007/s10067-017-3587-8</idno><idno type="wicri:Area/PubMed/Corpus">000C16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C16</idno><idno type="wicri:Area/PubMed/Curation">000C16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C16</idno><idno type="wicri:Area/PubMed/Checkpoint">000C29</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C29</idno><idno type="wicri:Area/Ncbi/Merge">001494</idno><idno type="wicri:Area/Ncbi/Curation">001494</idno><idno type="wicri:Area/Ncbi/Checkpoint">001494</idno><idno type="wicri:Area/Main/Merge">001901</idno><idno type="wicri:Area/Main/Curation">001902</idno><idno type="wicri:Area/Main/Exploration">001902</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.</title><author><name sortKey="Desplats, Marie" sort="Desplats, Marie" uniqKey="Desplats M" first="Marie" last="Desplats">Marie Desplats</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex, France. pascart.tristan@ghicl.net.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lomme</settlement></placeName></affiliation></author><author><name sortKey="Jelin, Germain" sort="Jelin, Germain" uniqKey="Jelin G" first="Germain" last="Jelin">Germain Jelin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Picardie</region><settlement type="city">Amiens</settlement></placeName></affiliation></author><author><name sortKey="Norberciak, Laurene" sort="Norberciak, Laurene" uniqKey="Norberciak L" first="Laurène" last="Norberciak">Laurène Norberciak</name><affiliation wicri:level="3"><nlm:affiliation>Department of biomedical research, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of biomedical research, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lomme</settlement></placeName></affiliation></author><author><name sortKey="Philippe, Peggy" sort="Philippe, Peggy" uniqKey="Philippe P" first="Peggy" last="Philippe">Peggy Philippe</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Houvenagel, Eric" sort="Houvenagel, Eric" uniqKey="Houvenagel E" first="Eric" last="Houvenagel">Eric Houvenagel</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, Saint Philibert Hospital, Rue du Grand But, 59462, Lomme Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lomme</settlement></placeName></affiliation></author><author><name sortKey="Goeb, Vincent" sort="Goeb, Vincent" uniqKey="Goeb V" first="Vincent" last="Goeb">Vincent Goeb</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Amiens University, University Hospital of Amiens-Picardie, Hôpital Nord Place Victor Pauchet, 80054, Amiens Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Picardie</region><settlement type="city">Amiens</settlement></placeName></affiliation></author><author><name sortKey="Flipo, Rene Marc" sort="Flipo, Rene Marc" uniqKey="Flipo R" first="René-Marc" last="Flipo">René-Marc Flipo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Lille University, CHRU Lille, 2 avenue Oscar Lambret, 59000, Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></analytic><series><title level="j">Clinical rheumatology</title><idno type="eISSN">1434-9949</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (administration & dosage)</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Patient Preference (statistics & numerical data)</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (administration et posologie)</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Antirhumatismaux (administration et posologie)</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Mâle</term><term>Perfusions veineuses</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Préférence du patient ()</term><term>Sujet âgé</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Preference</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Mâle</term><term>Perfusions veineuses</term><term>Préférence du patient</term><term>Sujet âgé</term><term>Études transversales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Choosing the subcutaneous (SC) route of administration of abatacept and tocilizumab is more cost-effective than the intravenous (IV) route. The objective of this study was to examine patients' reasons for choosing to keep with their IV infusions or to switch to subcutaneous SC injections. This study was based upon a self-administered questionnaire given to consecutive rheumatoid arthritis patients treated with abatacept or tocilizumab. Patients were asked to express their opinions concerning reasons explaining why they chose to keep the IV route or switch to the SC route. A total of 201 questionnaires completed by 127 patients treated by tocilizumab and 74 by abatacept were analysed. Overall, 45.8% of the patients chose to keep the IV route of administration. Another ongoing SC treatment was noted more often in patients choosing the SC route (15.9 versus 4.3%, p < 0.05). Reasons guiding the choice of the SC route were concerns about repeated hospital day-care (72%), greater autonomy with SC injections (38.7%) and economic considerations (21.5%). Reasons associated with choosing to maintain the IV route were worries about a lack of follow-up (72.1%), the absence of medical assistance during the SC injection (61.2%), maintaining social relationships with other patients developed at the hospital (40.5%), lower frequency of injection (32.9%), fear of adverse events (27.7%) and fear of SC injections (17.9%). Patients reject the SC switch from the IV route of tocilizumab and abatacept mainly because of fears about the unknown SC route, while those who accept it find it more convenient.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li><li>Picardie</li></region><settlement><li>Amiens</li><li>Lille</li><li>Lomme</li></settlement></list><tree><country name="France"><region name="Hauts-de-France"><name sortKey="Desplats, Marie" sort="Desplats, Marie" uniqKey="Desplats M" first="Marie" last="Desplats">Marie Desplats</name></region><name sortKey="Flipo, Rene Marc" sort="Flipo, Rene Marc" uniqKey="Flipo R" first="René-Marc" last="Flipo">René-Marc Flipo</name><name sortKey="Goeb, Vincent" sort="Goeb, Vincent" uniqKey="Goeb V" first="Vincent" last="Goeb">Vincent Goeb</name><name sortKey="Houvenagel, Eric" sort="Houvenagel, Eric" uniqKey="Houvenagel E" first="Eric" last="Houvenagel">Eric Houvenagel</name><name sortKey="Jelin, Germain" sort="Jelin, Germain" uniqKey="Jelin G" first="Germain" last="Jelin">Germain Jelin</name><name sortKey="Norberciak, Laurene" sort="Norberciak, Laurene" uniqKey="Norberciak L" first="Laurène" last="Norberciak">Laurène Norberciak</name><name sortKey="Pascart, Tristan" sort="Pascart, Tristan" uniqKey="Pascart T" first="Tristan" last="Pascart">Tristan Pascart</name><name sortKey="Philippe, Peggy" sort="Philippe, Peggy" uniqKey="Philippe P" first="Peggy" last="Philippe">Peggy Philippe</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001902 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001902 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28255739
|texte= Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28255739" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |